Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07206628 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Real-world Study to Assess Adherence to IOP Lowering Therapy in Patients With Glaucoma or Ocular Hypertension Using CONNECTDROP®

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Sep 2026 → Sep 2027
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from Laboratoires Thea

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Sep 2026 to Sep 2027v3 Show 5 more changesShow less
    • Primary endpoint(s) modified
    • Study completion pushed from Mar 2027 to Sep 2027
    • Study sites: 17 to 15
    • Eligibility criteria expanded, about 2 words
    • Study title expanded, about 4 words
  2. Study sites: 15 to 17v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this real-life, national, multicentre, prospective clinical investigation is to describe the adherence rate over time in patients with glaucoma or OHT already treated with IOP-lowering eye drops using connected device CONNECTDROP® The main questions it aims to answer are: * The mean annual adherence rate, defined as the percentage of the prescribed doses taken by the patient * The adherence profile of each patient * The association between the adherence profile, the objective adherence data and the clinical data. Participants will use the connected device CONNECTDROP® associated with the smartphone application on a daily basis.
Trial Details
NCT Number NCT07206628
Lead Sponsor Laboratoires Thea
Conditions
(from sponsor)		 Adherence to Glaucoma Therapy
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov